The FDA has issued a warning about counterfeit Ozempic, a diabetes medication often used for weight loss, which has recently infiltrated the market. After being alerted by Novo Nordisk, the producer of Ozempic, the FDA seized several hundred counterfeit units linked by a specific lot number but false serial numbers. Six adverse events were reported, raising concerns about safety associated with compromised products. This incident follows an earlier warning in 2023 about counterfeit Ozempic doses, emphasizing the ongoing issue of drug safety in the market.
The FDA and Novo Nordisk caution consumers to verify their Ozempic medications due to reports of counterfeit drugs entering the market, impacting patient safety.
Dave Moore, Executive Vice President of Novo Nordisk's U.S. Operations, emphasized that the company is taking the growing number of incidents involving counterfeit Ozempic very seriously.
The counterfeit products, while bearing an authentic lot number PAR0362, contain fake serial numbers starting with 51746517, leading to warnings about their safety.
Six adverse events connected to this batch of Ozempic have been reported; however, the specifics of the side effects linked to counterfeit doses remain unspecified.
Collection
[
|
...
]